Checkpoints in Glioblastoma Multiforme: a Research Progress and Prospect Analysis

Feng Yuan,Tao Li,Xuejun Yang

DOI: https://doi.org/10.3760/cma.j.issn.1671-8925.2018.12.015

2018-01-01

Abstract:Glioblastoma is the most common and most invasive primary malignant brain tumor in the central nervous system. Surgical resection, concurrent chemoradiotherapy and adjuvant chemotherapy are the standard treatment options, but the prognosis is very poor. It can be said that the standard treatment cannot safely and specifically eliminate all cancer cells, and only provide patients with limited survival benefits. Therefore, a large number of studies have attempted to use the natural cell killing ability of the immune system to aggressively attack the tumor, which is called "immunotherapy." This treatment concept has spawned a variety of treatment strategies, and is becoming another tumor treatment program after surgery, radiotherapy, chemotherapy and molecular targeted therapy. In recent years, antibodies against immune checkpoints have been shown to produce impressive clinical responses to non-small cell lung cancer, kidney cancer, melanoma, hematological tumors and other malignant tumors; it has raised interest in investigating whether these drugs are also effective in the field of brain tumors. Here, we summarize the current knowledge of central nervous system immune checkpoints and evaluate past and current immunological checkpoint treatment trials. And the future direction of treatment of immune checkpoints is discussed to provide new dawn for patients with malignant glioma.